Location & Type arrow_drop_up Concepts arrow_drop_down Orgs arrow_drop_down
Filter by Concept
#1
Jonathan Friedberg
Jonathan Friedberg
The coonsoldated Department of Psychatry, the Neuroscience Program, Harvard Medical School, Boston, Mass, Consolidated Department of Psychiatry, the Neuro‐science ...
Known for star star star star star
Indolent Lymphoma | Phase Iii | Free Survival | Evaluate Vitamin
#2
Fernando F. Cabanillas
Fernando F. Cabanillas
The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, U.S.A U.T.M.D. Anderson Cancer Center, Department of Hematology (Box 68), 1515 Holocombe ...
Known for star star star star star_border
Puerto Rico | Follicular Lymphoma | Molecular Response | Bone Marrow

#3
Nicolas Mounier
Nicolas Mounier
Onco-Haematology Department, Hospital l'Archet, 151 Route de Saint Antoine-Ginestière, 06000 Nice, France. mounier.n@chu-nice.fr
Known for star star star star star_border
Follicular Lymphoma | High-Dose Therapy | International Prognostic | Response Rate
#4
Julie Marie Vose
Julie Marie Vose
From the Section of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center the Department of Internal Medicine, Omaha Veterans Affairs ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Follicular Lymphoma | Speakers Bureau
#5
Jason Robert Westin
Jason Robert Westin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Unit 429, 1515 Holcombe Blvd, 77030, Houston, TX, USA
Known for star star star star star_border
Advisory Committees | Entitys Board | B-Cell Lymphoma | Speakers Bureau
#6
Eva K. Kimby
Eva K. Kimby
Department of Medicine, Section of Hematology, Danderyd Hospital, Danderyd, and the Department of Clinical Immunology, Huddinge Hospital, Huddinge, Sweden
Known for star star star star star_border
Follicular Lymphoma | Chronic Lymphocytic Leukemia | Advisory Committees | Rituximab Maintenance
#7
Krimo Bouabdallah
Krimo Bouabdallah
CHU Bordeaux, Service d’Hématologie et Thérapie Cellulaire, Bordeaux, France
Known for star star star star star_border
Advisory Committees | Entitys Board | Speakers Bureau | Intensive Chemotherapy
#8
Harald JR. Holte
Harald JR. Holte
From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Follicular Lymphoma | High-Dose Therapy
#9
Anca A. Prica
Anca A. Prica
From the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite ...
Known for star star star star star_border
Hematologic Malignancies | Advisory Committees | Drug Wastage | Entitys Board
#10
David C. Hodgson
David C. Hodgson
Division of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada, ; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada, ;
Known for star star star star star_border
Hodgkin Lymphoma | Radiation Therapy | Breast Cancer | Late Effects
#11
Eleanor Neal
Eleanor Neal
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Known for star star star star star_border
Baseline Pet | Rituximab Maintenance | Indolent Lymphoma | Immunologic Doublet
#12
Stacey Kalambakas
Stacey Kalambakas
Clinical Research Science, Celgene Corporation, Summit, United States
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii
#13
Ana Kostic
Ana Kostic
Juno Therapeutics, Inc., a Celgene Company, Seattle, WA
Known for star star star star star_border
Equity Ownership | Speakers Bureau | Lisocabtagene Maraleucel | Transcend Nhl
#14
Roswitha Forstpointner
Roswitha Forstpointner
Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany
Known for star star star star star_border
Follicular Lymphoma | Rituximab Maintenance | Response Duration | Stem Cells
#15
Chengqing Wu
Chengqing Wu
Statistics, Celgene International, Boudry, Switzerland
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii
#16
Steven W. Papish
Steven W. Papish
Hematology-Oncology Associates of Northern New Jersey, Morristown, NJ, USA,
Known for star star star star star_border
Speakers Bureau | Small Lymphocytic Lymphoma | Untreated Chronic Lymphocytic Leukemia | Sarah Cannon
#17
Roy Louis Maute
Roy Louis Maute
Institute of Cancer Genetics and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
Known for star star star star star_border
Anti-Cd47 Antibody | Orofacial Clefting | Mhc Class | Pd-1 Expression

 

Recently Asked Questions

View all FAQs

Myoclonic Epilepsy Myoclonic epilepsy is a type of seizure disorder that is characterized by brief, involuntary muscle movements. These movements can be isolated or occur in...

 

Performance Anxiety Performance anxiety is a type of fear that can cause individuals to feel overwhelmed or to have negative thoughts about their abilities. This can lead to...

 

A vaginal ulcer is a sore or lesion that develops on the lining of the vagina. Ulcers can be caused by a number of different things, including infection,...

 

Interstitial Pneumonia Interstitial pneumonia is a type of lung disease that occurs when the tissue between the alveoli (air sacs) becomes inflamed. This inflammation can cause...

 

Supracondylar Fracture A supracondylar fracture is a break in the distal (lower) end of the humerus, the bone in the upper arm. This type of fracture occurs just above the elbow,...

 

Whole Exome And Transcriptome Sequencing In 1042 Cases Reveals Distinct...

[ PUBLICATION ] Follicular Lymphoma (FL) is the most common indolent lymphoma derived from light zone germinal center B cells and characterized by a t(14;18) translocation resulting in upregulation of BCL2 in ...
Known for star star star star star
Follicular Lymphoma | Advisory Committees | Entitys Board | Genetic Alterations

A Phase I/ii Study Of Lenalidomide Plus Obinutuzumab In Relapsed Indolent Lymphoma

[ PUBLICATION ] Background: Patients with advanced indolent non-Hodgkin lymphoma (iNHL) can develop chemoresistance and most relapse following standard therapy. Although multiple treatment options exist, most ...
Known for star star star star star
Advisory Board | Relapsed Indolent Lymphoma | Consultancy Funding | Phase Portion

Two-Year Follow-Up Of Transcend Nhl 001, A Multicenter Phase 1 Study Of...

[ PUBLICATION ] Abstract Background : LBCLs are prevalent and aggressive subtypes of NHL, with limited treatment options and historically poor outcomes in the third- or later-line setting. Liso-cel is an ...
Known for star star star star star_half
Consultancy Honoraria | Speakers Bureau | Transcend Nhl | Advisory Committees

Cd5-Positive Marginal Zone Lymphoma: Clinical Characteristics Of The Mskcc...

[ PUBLICATION ] ... Zone Lymphoma (MZL) includes three subtypes of indolent lymphoma: splenic MZL, extranodal MZL of mucosa-associated lymphoid tissue (MALT) and nodal MZL. The diagnosis of MZL is often made ...
Known for star star star star star_half
Consultancy Funding | Marginal Zone | Cd5- Mzl | Seattle Genetics

Phase Ii Trial Of Response Adapted Ultra Low Dose (Uld) Orbital Radiation Therapy...

[ PUBLICATION ] Abstract Introduction: The standard of care for patients with stage IE indolent B-cell lymphoma (BCL) of the ocular adnexa is external beam radiotherapy (RT) to 24-30 Gy. Even with these ...
Known for star star star star star_half
Consultancy Funding | Response Adapted | Gilead Company | Bristol Myers Squibb

Long-Term Efficacy And Safety From The Copanlisib Chronos-1 Study In Patients...

[ PUBLICATION ] Abstract Introduction: We have previously reported that treatment of patients with relapsed or refractory indolent B-cell lymphoma with the pan-class I phosphatidylinositol 3-kinase ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Speakers Bureau | Consultancy Honoraria

An Open-Label, Randomized Study Of Bendamustine And Rituximab (Br) Compared With...

[ PUBLICATION ] Abstract Abstract 902 Background Bendamustine (B) is an active agent for relapsed and refractory indolent NHL, both as monotherapy and combined with ...
Known for star star star star star_half
Chop Cvp | Advisory Committees | Entitys Board | Indolent Nhl

Outcomes For Patients With Pre-Existing Diabetes Or Hypertension Treated With...

[ PUBLICATION ] Abstract Introduction: We previously reported that treatment of patients with relapsed or refractory indolent B-cell lymphoma with the pan-class I phosphatidylinositol 3-kinase (PI3K) ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Speakers Bureau | Membership Entity

Results Of A Phase I Trial Of Lenalidomide, Rituximab (R2) And Ixazomib For...

[ PUBLICATION ] ... with indolent B-cell lymphoma including follicular lymphoma (FL). Recent phase III data from the RELEVANCE trial comparing R2 to traditional chemoimmunotherapy showed that this regimen is ...
Known for star star star star star_half
Non-Hodgkin Lymphoma | Consultancy Honoraria | Proteasome Inhibitors | Relevance Trial

A Phase I Study Of Lenalidomide Plus A Next Generation Anti-Cd20 Antibody,...

[ PUBLICATION ] Abstract Background: Patients with advanced indolent non-Hodgkin lymphoma (iNHL) can develop chemoresistance and most relapse following standard therapy. Lenalidomide activates NK cells ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Generation Anti-Cd20 Antibody | Relapsed Indolent Lymphoma